BACKGROUND: @entity339 ( @entity339 ) is the most common @entity340 , and mitral valve surgery is the gold standard therapy for severe @entity339 . Many @entity1 with severe @entity339 are not referred for surgery because of old age, comorbidities, or severe @entity1002 . Transcatheter mitral valve implantation may be a better therapeutic option for these high-risk @entity1 with severe symptomatic @entity339 . OBJECTIVES: This study sought to describe the first-in- @entity1 series of transapical mitral valve implantation for @entity339 with the TIARA device. METHODS: Extensive preclinical ex  vivo and animal studies were conducted with the transapical mitral valve implantation of the Tiara system. The first 2 cases of @entity1 implantation were successfully performed in a 73-year-old @entity1 and a 61-year-old @entity1 with severe functional @entity339 . Both @entity1 were in New York Heart Association class IV @entity712 with @entity308 left ventricular ejection fraction, @entity120 , and additional comorbidities. RESULTS: The valve was implanted uneventfully in both @entity1 . General anesthesia and transapical access were used.  @entity1 were hemodynamically stable with no need for cardiopulmonary bypass. Immediately after implantation, systemic arterial pressure and @entity64 volume increased and pulmonary pressure decreased dramatically. There were no intraoperative complications, and both @entity1 were extubated in the operating room. Post-procedural echocardiograms at 48 h, 1 month, and 2 months demonstrated excellent prosthetic valve function with a low transvalvular gradient and no left @entity3585 . There was a trivial @entity2478 in the first @entity1 at 48 h, which was completely resolved at subsequent studies; no @entity2478 occurred in the second @entity1 . CONCLUSIONS: Transapical transcatheter mitral valve implantation is technically feasible and can be performed safely.  Early hemodynamic performance of the prosthesis was excellent. Transcatheter mitral valve implantation may become an important treatment option for @entity1 with severe @entity339 who are at high operative risk.

Short-Term Results of Transapical Transcatheter Mitral Valve Implantation for  XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'human', 'woman', 'patient', 'man'] @entity712 :: ('MESH:D006333', 'Disease') :: ['heart failure'] @entity339 :: ('MESH:D008944', 'Disease') :: ['Mitral regurgitation', 'MR', 'mitral regurgitation'] @entity308 :: ('MESH:D003866', 'Disease') :: ['depressed'] @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke'] @entity3585 :: ('MESH:D014694', 'Disease') :: ['ventricular outflow tract obstruction'] @entity2478 :: ('MESH:D019559', 'Disease') :: ['paravalvular leak'] @entity120 :: ('MESH:D006976', 'Disease') :: ['pulmonary hypertension'] @entity340 :: ('MESH:D006349', 'Disease') :: ['valvular heart disease'] @entity1002 :: ('MESH:D018487', 'Disease') :: ['left ventricular dysfunction']
@entity339 :: (MESH:D008944,Disease) :: ['Mitral Regurgitation']
